8-K ·Filed Jul 22, 2026

BDX

BECTON DICKINSON & CO
NEUTRAL
Impact 2/10
Horizonweeks Processed2mo ago SEC0001628280-26-049103
8-K context-dependent: Items 5.02, 7.01
Actionable Insight • Neutral

Monitor the appointment of the next Medical Essentials president for any strategic shifts. The direct reporting of BioPharma Systems to the CEO signals its importance as a growth driver, but no immediate trading catalyst is present.

DirectionNeutral
Confidencehigh
Horizonweeks
Latest settled — T+20d
BDX ▲ +22.49% at T+20d
NEUTRAL call ✓ call won +22.49% · α vs SPY +19.59% · entry $153.16 → $187.60
Next anchor: T+60d in 13d
Latest observation: T+49 +23.16% FF3 residual α
Entry anchored
Jul 21, 03:59 PM ET
via exchange tick
T+1d
-0.12%
call -0.12% · α +1.11%
$152.97
settled 2mo ago
T+5d
+9.95%
call +9.95% · α +12.35%
$168.40
settled 2mo ago
T+20d
+22.49%
call +22.49% · α +19.59%
$187.60
settled 6w ago
T+60d
—
call — · α —
—
in 13d

Price Chart

Loading chart...

Executive Summary

BDX announced the retirement of EVP and segment President Mike Garrison, effective Oct. 2, 2026, after 20+ years. The BioPharma Systems segment will report directly to CEO Tom Polen, streamlining the operating model. This is a routine executive transition with no financial impact; a search for the next Medical Essentials president is underway.

Key Facts

  • EVP Michael D. Garrison retiring after 20+ years, effective Oct. 2, 2026
  • BioPharma Systems segment will report directly to CEO Tom Polen going forward
  • Comprehensive search underway for next President of Medical Essentials segment
  • Garrison remains in role through end of fiscal year to support transition

Financial Impact

No financial figures disclosed; routine executive retirement with no material financial impact.

Risk Factors

  • Potential leadership vacuum if successor search is prolonged
  • Uncertainty around strategic direction of Medical Essentials segment under new leadership

Market Snapshot

Exchange
NYSE
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
43% bullish (21 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-049103
Document: bdnews_medessentialsbpsxpr.htm0001628280-26-049103
Document: 0001628280-26-049103-index-headers.html0001628280-26-049103
Document: 0001628280-26-049103-index.html0001628280-26-049103
Document: 0001628280-26-049103.txt0001628280-26-049103
9 reports for BDX
Performance horizon
Filters
Rows
Reports for BDX — sortable, filterable
TypeNow
Aug 14, 2026
7w ago
Insider Cluster
NEUTRAL ★ 2/10
$183.40 $182.91▼ −0.27%▲ +1.72%$177.07 (−3.45%)
Jul 22, 2026
10w ago
8-K
NEUTRAL ★ 2/10
$153.16 $187.60▲ +22.49%▲ +19.59%$177.07 (+15.61%)
Jun 27, 2026
13w ago
Insider Cluster
NEUTRAL ★ 2/10
$155.19 $156.36▲ +0.75%▲ +1.03%$177.07 (+14.10%)
Jun 27, 2026
13w ago
Insider Cluster
NEUTRAL ★ 2/10
$155.19 $156.36▲ +0.75%▲ +1.03%$177.07 (+14.10%)
Jun 3, 2026
17w ago
Insider Cluster
NEUTRAL ★ 2/10
$145.54 $152.90▲ +5.06%▲ +6.18%$177.07 (+21.67%)
May 29, 2026
18w ago
8-K
NEUTRAL ★ 4/10
$146.96 $155.92▲ +6.10%▲ +9.73%$177.07 (+20.49%)
Apr 2, 2026
26w ago
8-K
MIXED ★ 6/10
$155.23 $146.15▼ −5.85%▼ −14.83%$177.07 (+14.08%)
Mar 31, 2026
26w ago
Court Ruling
NEUTRAL ★ 2/10
$157.23 $145.31▼ −7.58%▼ −17.00%$177.07 (+12.62%)
Feb 25, 2026
31w ago
8-K
NEUTRAL ★ 5/10
$176.49 $157.17▼ −10.95%▼ −4.54%$177.07 (+0.33%)
Showing 9 of 9

US Market Status

Market Open — Closes in 6h 24m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access